EMA Application withdrawn: Tekinex (omacetaxine mepesuccinate) — ChemGenex Europe SAS

View source ↗

Summary

EMA withdrew the Tekinex application for omacetaxine mepesuccinate (ChemGenex Europe SAS) for chronic myeloid leukemia with BCR-ABL positive status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• Tekinex (omacetaxine mepesuccinate)

Snippet

Status: Application withdrawn. Therapeutic area: Leukemia, Myelogenous, Chronic, BCR-ABL Positive. MAH: ChemGenex Europe SAS. Decision date: 31/01/2011